Core Viewpoint - Quantum BioPharma Ltd. is seeking shareholder approval for a non-brokered private placement of class A multiple voting shares for gross proceeds of up to $600 million, with the meeting scheduled for September 26, 2025 [1][2]. Group 1: Offering Details - The entire offering is expected to be subscribed by existing holders of MVS and is anticipated to close on or about September 26, 2025, pending shareholder approval [2]. - Proceeds from the offering will be used for general working capital purposes [2]. - All securities issued will be subject to a statutory hold period of four months plus a day from issuance in accordance with Canadian securities laws [2]. Group 2: Company Overview - Quantum BioPharma is focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [5]. - The company’s lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation, a key factor in multiple sclerosis, and is currently in preclinical models [5]. - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which includes a royalty agreement of 7% on sales until total payments reach $250 million, after which the royalty will drop to 3% [5].